Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Indoleamine 2,3 dioxygenase 1 (IDO 1) is the major enzyme catabolising the Tryptophan outside
the liver. It has been shown that its plays a important role in generating a
immunosuppressive micro-environment in tumors. IDO expression has been shown by Hennequart et
al. to be driven by Cyclooxygenase-2 (COX-2) expression. The investigator's team also shown
that anti-COX2, celecoxib, can in a xenograft models of ovarian cancer decrease IDO1
expression and result in an infiltration of the tumor by T cells. The investigator proposed
then to conduct a proof of concept study to evaluate the effect of pre-operative short
administration of Celecoxib on IDO expression and Immune cells tumors infiltration, in
patients with endometrial cancer. Indeed, this tumor type is well known to express frequently
a high level of IDO.
Phase:
Phase 2
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain